BNP Paribas Knock-Out MRK/ DE000PC24LZ3 /
18/09/2024 19:20:42 | Chg.-0.090 | Bid19:32:07 | Ask19:32:07 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.510EUR | -1.96% | 4.510 Bid Size: 42,000 |
4.520 Ask Size: 42,000 |
Merck and Co Inc | 169.2694 USD | 31/12/2078 | Put |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28/05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23/05
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14/05
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08/05
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24/04
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness